drugset / Trial / NCT05256381
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.
Timeline
- Start
- 2022-06-21
- Primary completion
- 2024-08-31
- Completion
- 2024-11-29
Outcome
Missed primary endpoint
Stopped: “Due to lack of expected efficacy shown at the time of the interim analysis”
release “Interim data from SOTIO’s clinical trials of nanrilkefusp alfa have shown insufficient efficacy to warrant further development in larger randomized trials in these specific indications and combinations.” sotio.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nanrilkefusp alfa | Protein / enzyme biologic | 12 ug/kg | Subcutaneous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |